The Role and Intervention of TGF-β in Abdominal Radiation Injury

Phase 2

• Conditions: Radiotherapy Side Effect; Taking Captopril
• Interventions: Drug: Captopril 12.5 Mg

• Registration Number: NCT03613506
• Lead Sponsor: Wuhan University

Brief Summary

This project aims to investigate the relationship between radiation-induced the relationship between elevated peripheral blood TGFβ and complications of radiotherapy,and to analysis of changes in peripheral blood TGFβ levels after abdominal radiotherapy and its relationship with radiotherapy complications.Simultaneously,Patients who underwent abdominal radiotherapy were given captopril (sustained release) to block TGFβ,Whether it can reduce peripheral blood TGFβ levels and reduce radiotherapy complications,to explore the protective effect of blocking TGFβ secretion on normal tissues after radiotherapy.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2018-07-23
• Study First Submitted QC: 2018-08-01
• Study First Posted: 2018-08-03
• Study Start: 2019-10-25
• Status Verified: 2022-01
• Last Update Submitted: 2022-01-29
• Last Update Posted: 2022-02-14
• Primary Completion: 2022-06-25
• Study Completion: 2022-12-25

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 226

Inclusion Criteria

1. Informed consent form for this study has been signed
2. Age 18-70 years old, gender is not limited，Pathological diagnosis of patients with advanced malignant tumors，Radiotherapy indications；
3. BED (α/β=10)≥50；ECOG score 0-2；Blood routine：WBC≥3.5×109/L,GRAN≥2.0×109/L,Hb≥90g/L，PLT≥100×109/L;
4. Liver function: ALT or AST ≤ 2.5 times the normal high value (ULN)；Bilirubin ≤ 1.5 × ULN, serum APK ≤ 2.5 × ULN;
5. Renal function：Serum creatinine ≤1.5×ULN, and creatinine clearance ≥60ml/min
6. No organ transplant history
7. Women of childbearing age must undergo a urine pregnancy test within 7 days prior to initiation of treatment and the results are negative and not in lactation
8. Male and female patients of childbearing age agreed to adopt a reliable method of contraception before entering the trial and during the study until 30 days after stopping the drug.

Exclusion Criteria

1. Patients undergoing chemotherapy or targeted therapy at the same time
2. Long-term use of ACEI or ARB drugs for hypertension
3. This radiotherapy site has been treated with radiotherapy；Combined with severe heart disease or major organ failure
4. Have a history of drug abuse or alcohol addiction
5. Combined active infection
6. Combined with severe malnutrition or severe anemia
7. Human immunodeficiency virus (HIV) infection
8. During pregnancy or lactation
9. Those who are unable to tolerate or may be allergic to the drugs used in this study；Persons without civil capacity or limited capacity for civil conduct；
10. Researchers believe that it is not suitable for inclusion

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Peripheral blood TGF-β content before and after radiotherapy	Captopril 12.5 Mg	-

Primary Outcome Measures

Name	Time	Method
Study the effect of abdominal radiation therapy on peripheral blood TGFβ levels	12 weeks	The levels of TGF-β in peripheral blood of patients before and after radiotherapy were compared.
Blocking TGFβ for protective effect on normal tissues	12 weeks	Give two groups of patients captopril (sustained release) 12.5mg b.i.d. for two months,comparing their levels of TGF-β in peripheral blood

Trial Locations

Locations (1)

Jin Peng; 🇨🇳 Wuhan, Hubei, China